HOWL vs. INZY, NKTR, RAPT, VNDA, NBTX, AKBA, VTYX, XERS, PYXS, and EPIX
Should you be buying Werewolf Therapeutics stock or one of its competitors? The main competitors of Werewolf Therapeutics include Inozyme Pharma (INZY), Nektar Therapeutics (NKTR), RAPT Therapeutics (RAPT), Vanda Pharmaceuticals (VNDA), Nanobiotix (NBTX), Akebia Therapeutics (AKBA), Ventyx Biosciences (VTYX), Xeris Biopharma (XERS), Pyxis Oncology (PYXS), and ESSA Pharma (EPIX). These companies are all part of the "pharmaceutical preparations" industry.
Inozyme Pharma (NASDAQ:INZY) and Werewolf Therapeutics (NASDAQ:HOWL) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, community ranking, risk, valuation, profitability, earnings, analyst recommendations and institutional ownership.
Werewolf Therapeutics has higher revenue and earnings than Inozyme Pharma. Werewolf Therapeutics is trading at a lower price-to-earnings ratio than Inozyme Pharma, indicating that it is currently the more affordable of the two stocks.
88.3% of Inozyme Pharma shares are held by institutional investors. Comparatively, 64.8% of Werewolf Therapeutics shares are held by institutional investors. 11.9% of Inozyme Pharma shares are held by company insiders. Comparatively, 21.1% of Werewolf Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
In the previous week, Inozyme Pharma had 17 more articles in the media than Werewolf Therapeutics. MarketBeat recorded 30 mentions for Inozyme Pharma and 13 mentions for Werewolf Therapeutics. Inozyme Pharma's average media sentiment score of 0.24 beat Werewolf Therapeutics' score of 0.23 indicating that Werewolf Therapeutics is being referred to more favorably in the news media.
Inozyme Pharma received 12 more outperform votes than Werewolf Therapeutics when rated by MarketBeat users. Likewise, 81.40% of users gave Inozyme Pharma an outperform vote while only 62.16% of users gave Werewolf Therapeutics an outperform vote.
Inozyme Pharma has a net margin of 0.00% compared to Inozyme Pharma's net margin of -256.33%. Inozyme Pharma's return on equity of -36.15% beat Werewolf Therapeutics' return on equity.
Inozyme Pharma presently has a consensus price target of $17.00, suggesting a potential upside of 274.45%. Werewolf Therapeutics has a consensus price target of $12.00, suggesting a potential upside of 137.62%. Given Werewolf Therapeutics' higher probable upside, equities analysts clearly believe Inozyme Pharma is more favorable than Werewolf Therapeutics.
Inozyme Pharma has a beta of 1.54, indicating that its share price is 54% more volatile than the S&P 500. Comparatively, Werewolf Therapeutics has a beta of 0.71, indicating that its share price is 29% less volatile than the S&P 500.
Summary
Inozyme Pharma beats Werewolf Therapeutics on 9 of the 16 factors compared between the two stocks.
Get Werewolf Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for HOWL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HOWL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Werewolf Therapeutics Competitors List
Related Companies and Tools
